PMID:
Biomed Pharmacother. 2020 Jan ;121:109646. Epub 2019 Nov 15. PMID: 31739162
Abstract Title:
Protective effects of Corbrin Capsule against permanent cerebral ischemia in mice.
Abstract:
Corbrin Capsule is a traditional Chinese patent medicine with the main component of fermentative cordyceps fungus powder (Cs-C-Q80). The indications of Corbrin Capsule include chronic renal insufficiency, chronic obstructive pulmonary (COPD), pulmonary fibrosis, and chronic bronchitis. However, the effects of Corbrin Capsule on acute cerebral ischemia are still unclear. The objective of this study was to explore the preventive effect of Corbrin Capsule in permanent and transient middle cerebral artery occlusion (MACO) mice model. Male C57BL/6 mice were given Corbrin of 0.04, 0.2 and 1 mg/kg by gavage once a day for 3, 7 or 14 days and then subjected to pMCAO or tMCAO. Infarct volumes, neurological deficit score, ATP concentration, SOD activity and MDA content were assessed. Results showed that prolonged pretreatment with Corbrin (1.0 mg/kg) to 7 days or more effectively ameliorated brain infarct and neurological scores in pMCAO mice. Shorter (3 days) or without pretreatment of Corbrin was invalid, suggesting a pretreatment time window. The ATP concentration was significantly increased with effective Corbrin pretreatments in ischemic brains, while the content of MDA sharply decreased in Corbrin groups. In tMCAO mice, Corbrin showed no neuroprotection even with pretreatment. In conclusion, long-term pre-administration of Corbrin Capsule is necessary for its anti-cerebral ischemic effects, and the underlying mechanisms might be associated with increase of ATP concentration and the anti-inflammatory effects in ischemic brain tissue.
Health Time 